Interested in being part of a dynamic team to develop and bring new home-based diagnostic tests to the market? We are looking for a potential CEO and Co-founder!
We are researchers from KTH Royal Institute of Technology. We have developed a device based on microneedles for taking a tiny biofluid sample from the skin in a minimally invasive manner.
Our device provides a painless and more comfortable alternative to drawing blood, to run screening and diagnostics tests. Instead of blood, we sample skin interstitial fluid (ISF), an information-rich fluid, which has shown potential to substitute blood for monitoring of a wide variety of markers and metabolites.
Our mission is to enable patients to conveniently take their sample without pain, without large needles, with lower infection risk, and to do so at home or at the point-of-care (PoC).
Our technology (patent pending) enables self-sampling of ISF, using a device which extracts, measures the liquid volume, and stores it in a stable form. The sample can be then shipped to a laboratory for analysis without need for refrigeration or be treated as biohazardous, simplifying the logistics.
Our goal is to bring this technology to the market within 2-3 years and ultimately provide a new testing platform replacing blood sampling in a range of application areas, e.g. drug abuse screening, sampling for those afraid of needles, usage in clinical trials, or simple sampling in home environments.
What we have accomplished:
The journey ahead
We are still at an early stage but are working on developing the technology for various use cases and, in the future, expanding into PoC testing devices for certain applications. In parallel to this work, we need to initiate more business development activities and raise funding, and this is where you come in!
We see several market opportunities for our sampling device and multiple possible products, with different potential business models and strategies. We need to decide on the best market entry strategies, the best initial application area, and in parallel pursue clinical validation of our technology as well as start up our device manufacturing.
This is where you can make a difference and play a crucial role. We are looking for a candidate who can help to raise funding, lead the business development, establish customer agreements and relationships, and take on the CEO role to establish a company.
What we offer
We offer an opportunity to join a start-up with unique technology based on research at KTH and with many market opportunities, where you can drive the business’ development and direction. We seek someone that wants to join a highly aspiring start-up as co-founder with all the associated risks and rewards. Until initial funding is secured, you will be primarily incentivized via ownership in the company.
Your level of involvement depends on gained traction, customer interest and funding but we expect you to initially spend at least 25% of your full time on the project and be able to ramp this up to full time. The initial period of a few months will be as a consulting assignment with a limited fixed payment.
We seek a business developer with the potential and desire to take on the CEO role. We expect you to be an entrepreneur that takes the company to the next phase.
Your responsibilities will include:
We expect you to have:
Meriting skills include:
We believe in diversity and therefore welcome all applicants regardless of gender, background , orientation and beliefs.
Business Development Coach from KTH
Centrally located office space (KTH Campus)
Be part of the thriving KTH Innovation Community
Access to mentor and investor network
Workshops and service packs from KTH partners
Access to Media Studio and Makerspace
Minvasive is currently supported by KTH Innovation and part of a batch in the Pre-incubator program. The KTH Innovation Pre-incubator program is a 12 month program to accelerate the development of promising startup projects from KTH Royal Institute of Technology. Startup projects receive extensive support from inhouse Business Development Coaches as well as additional support such as office space, community activities, team development support, funding schemes, IP and legal counseling, access to industry, mentor and investor networks.
Mininvasive is set to operate and expand within a large worldwide market bridging blood sampling (valued 11 billion US$ yearly), PoC diagnostics (20 B$), and homecare (350 B$), with possibilities to diversify and extend its offer to various aspects of point-of-care sampling and testing.